Funder
Natural Science Foundation of Changzhou Municipality
Natural Science Foundation of Hunan Province
Reference51 articles.
1. Lung cancer immunotherapy: progress, pitfalls, and promises;Lahiri;Mol. Cancer,2023
2. First-line immunotherapy for non–small-cell lung cancer;Reck;J. Clin. Oncol.,2022
3. The cutting-edge progress of immune-checkpoint blockade in lung cancer;Zhou;Cell. Mol. Immunol.,2021
4. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017
5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016